Bortezomib, free base, 100mg
To Order Contact us: lieven@wlsolutions.be
Bortezomib |
||
| 100100 | 100.0mg | EUR 90 |
Bortezomib |
||
| 27028 | 10 mg | EUR 150 |
|
Description: Potent (Ki, 0.6 nM), specific and reversible proteasome inhibitor; no significant inhibitory activity against other enzymes or receptors. Bortezomib inhibits cell proliferation of H460 cells (human non-small cell lung cancer cell lines) with an IC50 of 0.1 µM and has been associated with suppresion of prostate cancer cell lines with an IC90 of 10 nM. _x000D_ |
||
Bortezomib |
||
| B675700 | 100mg | EUR 74 |
|
Description: 179324-69-7 |
||
Bortezomib |
||
| 20-abx185366 |
|
|
Bortezomib |
||
| 20-abx076697 |
|
|
Bortezomib |
||
| abx076697-50rxns | 50 rxns | EUR 131.25 |
Bortezomib |
||
| HY-10227 | 50mg | EUR 116.88 |
|
Description: Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2]. |
||
Bortezomib |
||
| GP0262 | 5mg | EUR 273.72 |
Bortezomib |
||
| GP0262-25 | 25 | EUR 216.3 |
Bortezomib |
||
| GP0262-25MG | 25 mg | EUR 246 |
Bortezomib |
||
| GP0262-5 | 5 | EUR 98.4 |
Bortezomib |
||
| GP0262-5MG | 5 mg | EUR 112.8 |
Bortezomib |
||
| MBS3602704-100mg | 100mg | EUR 260 |
Bortezomib |
||
| MBS3602704-10mg | 10mg | EUR 200 |
Bortezomib |
||
| MBS3602704-200mg | 200mg | EUR 320 |
Bortezomib |
||
| MBS3602704-25mg | 25mg | EUR 215 |
Bortezomib |
||
| MBS3602704-50mg | 50mg | EUR 220 |
Bortezomib |
||
| MBS808033-25mg | 25mg | EUR 225 |
Bortezomib |
||
| MBS808033-5mg | 5mg | EUR 185 |
Bortezomib |
||
| MBS808033-5x25mg | 5x25mg | EUR 745 |
Bortezomib |
||
| MBS808033-5x5mg | 5x5mg | EUR 580 |
Bortezomib |
||
| T2399-10mg | 10mg | Ask for price |
|
Description: Bortezomib |
||
Bortezomib |
||
| T2399-1g | 1g | Ask for price |
|
Description: Bortezomib |
||
Bortezomib |
||
| T2399-1mg | 1mg | Ask for price |
|
Description: Bortezomib |
||
Bortezomib |
||
| T2399-50mg | 50mg | Ask for price |
|
Description: Bortezomib |
||
Bortezomib |
||
| T2399-5mg | 5mg | Ask for price |
|
Description: Bortezomib |
||
Bortezomib |
||
| SIH-328-25MG | 25 mg | EUR 76.8 |
Bortezomib |
||
| SIH-328-5MG | 5 mg | EUR 40.8 |
Bortezomib, 99% |
||
| BC010-005 | 5mg | Ask for price |
Bortezomib, 99% |
||
| BC010-010 | 10mg | EUR 115 |
Bortezomib, 99% |
||
| BC010-025 | 25mg | EUR 145 |
Bortezomib, 99% |
||
| BC010-050 | 50mg | EUR 186 |
Bortezomib, 99% |
||
| BC010-500 | 500mg | EUR 440 |
Bortezomib-d8 |
||
| HY-10227S | 1 mg | EUR 811.7 |
|
Description: Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2]. |
||
Bortezomib Trimer |
||
| B675720 | 10mg | EUR 195 |
|
Description: 390800-88-1 |
||
Bortezomib (Velcade) |
||
| MBS385123-100mg | 100mg | EUR 245 |
Bortezomib (Velcade) |
||
| MBS385123-10mg | 10mg | EUR 145 |
Bortezomib (Velcade) |
||
| MBS385123-1mLinDMSO | 1mL(inDMSO) | EUR 140 |
Bortezomib (Velcade) |
||
| MBS385123-25mg | 25mg | EUR 185 |
Bortezomib (Velcade) |
||
| MBS385123-5mg | 5mg | EUR 115 |
(1R,2R)-Bortezomib |
||
| B675705 | 50mg | EUR 198 |
|
Description: 1132709-15-9 |
||
(1S,2R)-Bortezomib |
||
| B675710 | 100mg | EUR 81 |
|
Description: 1132709-16-0 |
||
(1S,2S)-Bortezomib |
||
| B675715 | 10mg | EUR 236 |
|
Description: 1132709-14-8 |
||
(1S,2S)-Bortezomib |
||
| HY-135396 | 1 mg | EUR 378.79 |
|
Description: (1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a cell-permeable, reversible, and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki of 0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is an anti-cancer agent and the first therapeutic proteasome inhibitor to be used in humans[1][2][3]. |
||
(1S,2S)-Bortezomib |
||
| MBS5765873-1mg | 1mg | EUR 190 |
(1S,2S)-Bortezomib |
||
| MBS5765873-2mg | 2mg | EUR 255 |
(1S,2S)-Bortezomib |
||
| MBS5765873-5mg | 5mg | EUR 345 |
(1S,2S)-Bortezomib |
||
| T10061-10mg | 10mg | Ask for price |
|
Description: (1S,2S)-Bortezomib |
||
(1S,2S)-Bortezomib |
||
| T10061-1g | 1g | Ask for price |
|
Description: (1S,2S)-Bortezomib |
||
(1S,2S)-Bortezomib |
||
| T10061-1mg | 1mg | Ask for price |
|
Description: (1S,2S)-Bortezomib |
||
(1S,2S)-Bortezomib |
||
| T10061-50mg | 50mg | Ask for price |
|
Description: (1S,2S)-Bortezomib |
||
(1S,2S)-Bortezomib |
||
| T10061-5mg | 5mg | Ask for price |
|
Description: (1S,2S)-Bortezomib |
||
Bortezomib (PS-341) |
||
| A2614-10 | 10 mg | EUR 48 |
|
Description: Ubiquitination/ Proteasome|Proteasome |
||
Bortezomib (PS-341) |
||
| A2614-100 | 100 mg | EUR 200 |
|
Description: Ubiquitination/ Proteasome|Proteasome |
||
Bortezomib (PS-341) |
||
| A2614-25 | 25 mg | EUR 86.4 |
|
Description: Ubiquitination/ Proteasome|Proteasome |
||
Bortezomib (PS-341) |
||
| A2614-5.1 | 10 mM (in 1mL DMSO) | EUR 44 |
|
Description: Ubiquitination/ Proteasome|Proteasome |
||
Bortezomib (PS-341) |
||
| A2614-500 | 500 mg | EUR 544 |
|
Description: Ubiquitination/ Proteasome|Proteasome |
||
Bortezomib (PS-341) |
||
| A2614-S | Evaluation Sample | EUR 24 |
|
Description: Ubiquitination/ Proteasome|Proteasome |
||
Bortezomib (PS-341) |
||
| MBS130987-100mg | 100mg | EUR 1065 |
Bortezomib (PS-341) |
||
| MBS130987-500mg | 500mg | EUR 2775 |
Bortezomib (PS-341) |
||
| MBS575292-100mg | 100mg | EUR 220 |
Bortezomib (PS-341) |
||
| MBS575292-10mg | 10mg | EUR 150 |
Bortezomib (PS-341) |
||
| MBS575292-25mg | 25mg | EUR 160 |
Bortezomib (PS-341) |
||
| MBS575292-50mg | 50mg | EUR 175 |
Bortezomib (PS-341) |
||
| MBS575292-5mg | 5mg | EUR 140 |
Bortezomib-pinanediol |
||
| 565251 | 5.0mg | EUR 265 |
Bortezomib-pinanediol |
||
| MBS3611089-10mg | 10mg | EUR 420 |
Bortezomib-pinanediol |
||
| MBS3611089-25mg | 25mg | EUR 665 |
Bortezomib-pinanediol |
||
| MBS3611089-5mg | 5mg | EUR 330 |
Bortezomib-pinanediol |
||
| MBS3611089-5x25mg | 5x25mg | EUR 2660 |
Bortezomib-pinanediol |
||
| MBS5758717-10mg | 10mg | EUR 355 |
Bortezomib-pinanediol |
||
| MBS5758717-1mg | 1mg | EUR 180 |
Bortezomib-pinanediol |
||
| MBS5758717-25mg | 25mg | EUR 590 |
Bortezomib-pinanediol |
||
| MBS5758717-2mg | 2mg | EUR 215 |
Bortezomib-pinanediol |
||
| MBS5758717-5mg | 5mg | EUR 260 |
Bortezomib-pinanediol |
||
| T7854-10mg | 10mg | Ask for price |
|
Description: Bortezomib-pinanediol |
||
Bortezomib-pinanediol |
||
| T7854-1g | 1g | Ask for price |
|
Description: Bortezomib-pinanediol |
||
Bortezomib-pinanediol |
||
| T7854-1mg | 1mg | Ask for price |
|
Description: Bortezomib-pinanediol |
||
Bortezomib-pinanediol |
||
| T7854-50mg | 50mg | Ask for price |
|
Description: Bortezomib-pinanediol |
||
Bortezomib-pinanediol |
||
| T7854-5mg | 5mg | Ask for price |
|
Description: Bortezomib-pinanediol |
||
Bortezomib-D8 (Major) |
||
| B675702 | 10mg | EUR 339 |
Bortezomib Impurity 11 |
||
| B973910 | 10mg | EUR 450 |
|
Description: 862895-00-9 |
||